Skip to main content

Table 2 Univariate and multivariate analyses of OS with Cox regression models

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Covariate

Univariate analysis (n = 65)

Multivariate analysis (n = 65)

HR

95% C.I.

P-value

HR

95% C.I.

P-value

Group

 irAE

Reference

   

Reference

   

 non-irAE

6.081

2.373

15.582

< 0.001

9.543

3.336

27.302

< 0.001

ECOG PS

 0

Reference

   

Reference

   

  ≥ 1

2.673

0.960

7.444

0.060

1.271

0.425

3.805

0.622

Number of metastatic sites

  < 2

Reference

   

Reference

   

  ≥ 2

1.465

0.763

2.812

0.251

2.147

1.016

4.538

0.045

ALP

 Low

Reference

   

Reference

   

 High

2.259

1.284

3.97.3

0.005

2.499

1.272

4.913

0.008

Disease status

 Recurrence

Reference

   

Reference

   

 Stage IV

1.584

0.915

2.743

0.101

0.813

0.420

1.577

0.541

NLR

 Low (< 4)

Reference

   

Reference

   

 High (≥4)

1.716

0.991

2.971

0.054

1.551

0.810

2.971

0.185

  1. ALP alkaline phosphatase, ECOG PS Eastern Cooperative Oncology Group Performance Status, irAE immune-related adverse event
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us